PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELTECIMOD AS COMPARED TO PLACEBO IN ADDITION TO STANDARD OF CARE IN PATIENTS WITH SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY (SA-AKI) Save

Date Added
April 9th, 2019
PRO Number
Pro00086843
Researcher
Heather Evans

List of Studies

Silhouette
Keywords
Infectious Diseases, Kidney
Summary

The purpose of the study is to test the effectiveness and safety of Reltecimod, an investigational drug, on patients with acute kidney injury associated with serious infections. The drug will be administered at a dose of 0.5 mg/kg as an intravenous infusion given over 10 minutes. There are a total of 10 study visits- only one of which involves IMP administration. The other nine visits are for follow-up of the participant's condition over a three month period. The majority of these visit will be completed by the end of the fist 30 days of the participants' trial timeline.

Institution
MUSC
Recruitment Contact
Jason Hirsch
843-792-8824
hirschj@musc.edu

Change_preferences

-- OR --

Create_login